Breast Cancer 

Identifying Resistant Subpopulations in “Standardized” Breast Cancer Cell Lines via 4D Functional Tracking

Case Study: High-Resolution Functional Profiling of MCF-7 and MDA-MB-231

In a large-scale comparative study, we leveraged our 4D AI model to analyze 1.5 million single-cell biographies across standard breast cancer cell line models. While these cell lines are typically characterized using bulk genomic signatures, our platform revealed substantial functional heterogeneity and distinct subpopulations within each cohort.

With this approach, we identified a high-risk Dormant Persister cluster characterized by sustained metabolic signaling and preserved membrane integrity. Notably, this subpopulation demonstrated broad therapeutic resilience, maintaining high viability across a diverse pharmacological spectrum, including cytotoxic chemotherapies, targeted inhibitors, immunotherapies, and next-generation antibody–drug conjugates (ADCs).

In the MDA‑MB‑231 model, we mapped the emergence of three functional states within 48 hours, including Fragile Responders (apoptosis-prone), Dormant Persisters (quiescent, drug-tolerant), and high-risk Active Escapers (refractory, proliferative).

These findings demonstrate that even “standardized” cell line models can harbor significant functional diversity. By distinguishing Fragile Responders from Dormant Persisters and Active Escapers, our platform provides a powerful foundation for early-stage preclinical studies of drug response and resistance. Importantly, it enables detection of “hidden” persister populations that are often missed by conventional endpoint assays.

Data Visulization

Visualizing the functional responses between therapeutic success and drug resistance profile.

4D Functional Scatter Map

Red Zone : The “Death Zone”
Green Zone : The “Active / Resistant Zone”
Neutral Zone : The “Persistence Zone”

The 4D Scatter Maps translate millions of individual cell biographies into a high-fidelity roadmap of drug response nased on morphological and phenotypic features to identify the rare sub-populations with resistance.

4D Distribution Curve Plot

Red Zone : The “Death Zone”
Green Zone : The “Active / Resistant Zone”
Neutral Zone : The “Persistence Zone”

By overlaying 60+ treatment conditions, we move beyond the limitations of ‘average’ numerical data to provide a review on Potency Audit. While standard assays mask critical details behind a single mean value, our distribution curves reveal the true heterogeneity of the cellular population.

Strategic Application

1. Kinetic Profiling of Targeted Therapeutics & ADCs


Challenges in Market : Determining the spatial and temporal efficacy of Antibody-Drug Conjugates (ADCs) beyond simple endpoint viability.

Platform Capability : We track the discrete stages of the therapeutic lifecycle—from membrane binding to intracellular payload release and the resulting metabolic decay.

Scientific Value : Quantify the “Sequestration Phenotype” of sub-populations that internalize the conjugate but bypass the apoptotic pathway. This allow the optimization of linker stability and payload potency based on functional fate mapping.

2. Functional Synergy Predictor in Combination Discovery


Analytical Challenge: Identifying true synergistic interactions that eliminate refractory reservoirs rather than merely increasing the overall kill rate.

Platform Capability: Our models map the Population Architecture post-treatment. We identify “Synergy Gaps” where a secondary agent fails to neutralize the Active Escaper population (Green Zone) left by the primary therapy.

Scientific Value: Provide a robust and single-cell biological rationale for therapeutic combinations, ensuring that the final regimen is designed to prevent emergent resistance.

3. Longitudinal Studies of Persistence and Recurrence

Analytical Challenge : Characterizing the quiescent “Persister” state, a non-proliferative, metabolically altered cell population that drives late-stage clinical relapse.

Platform Capability : Leveraging our 96-well longitudinal tracking, we observe cellular recovery during “drug holidays” or extended treatment cycles (7–21 days).

Scientific Value : Discriminate between transient quiescence and terminal senescence. By capturing the kinetic biography of the Neutral Zone (Quiescent) population, we can predict the velocity and phenotype of post-treatment recurrence.

Accelerating the Path from Discovery to the Clinic

We invite the global pharma and biotechnology partners to leverage our 4D AI-driven platform as a strategic extension of their drug discovery pipeline.

By providing high-dimensional functional insights , we assist our partners de-risk their most promising candidates and optimize therapeutic strategies at early preclinical stage.